Beijing GoBroad Hospital is the lead sponsor of 32 current clinical trials in our China register. 26 are recruiting patients now. The most common phase is Phase 1/2. The drugs named most often in its trials are CT041 autologous CAR T-cell, Cyclophosphamide and Fludarabine. The most-studied condition is Acute Lymphoblastic Leukemia, in Relapse.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
NCT07003555 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | Recruiting | 2025-05 | China |
|
One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL
NCT06618313 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
|
Not applicable | Recruiting | 2025-03 | China |
|
CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)
NCT06822881 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
|
Phase 1 | Recruiting | 2025-02 | China |
|
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537 · ClinicalTrials.gov ↗ · Systemic Sclerosis (SSc), Primary Sjogren's Syndrome
|
Phase 1 | Recruiting | 2025-10 | China |
|
Clinical Study on the Safety and Efficacy of BiTE-EV in Relapsed/Refractory Acute B-Cell Leukemia
NCT06890494 · ClinicalTrials.gov ↗ · Leukemia
|
Phase EARLY_PHASE1 | Recruiting | 2025-01 | China |
|
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460 · ClinicalTrials.gov ↗ · Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
|
Phase 1/2 | Recruiting | 2025-04 | China |
|
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
NCT07003568 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma (RRMM)
|
Phase 1 | Recruiting | 2025-05 | China |
|
Exploratory Clinical Study on the Safety of STR-P004
NCT07143617 · ClinicalTrials.gov ↗ · Autoimmune Diseases
|
Not applicable | Recruiting | 2025-09 | China |
|
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
NCT07070323 · ClinicalTrials.gov ↗ · T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | 2025-07 | China |
|
To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma
NCT07179484 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma
|
Observational | Recruiting | 2025-10 | China |
|
CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT06925464 · ClinicalTrials.gov ↗ · T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
|
Phase 1/2 | Recruiting | 2025-04 | China |
|
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
|
Phase 2 | Recruiting | 2024-08 | China |
|
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
NCT06389305 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
|
Not applicable | Recruiting | 2024-05 | China |
|
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
NCT06980597 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc)
|
Phase 1 | Recruiting | 2025-06 | China |
|
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT06688799 · ClinicalTrials.gov ↗ · Autoimmune Diseases
|
Phase 1/2 | Recruiting | 2024-11 | China |
|
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
NCT07022964 · ClinicalTrials.gov ↗ · T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
|
Phase 1/2 | Recruiting | 2025-06 | China |
|
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
NCT06947473 · ClinicalTrials.gov ↗ · Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
|
Phase 1/2 | Recruiting | 2026-03 | China |
|
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
NCT06326021 · ClinicalTrials.gov ↗ · Refractory/Relapsed Acute Myeloid Leukaemia
|
Phase 1 | Recruiting | 2024-04 | China |
|
Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients
NCT06343090 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
|
Not applicable | Recruiting | 2024-04 | China |
|
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
NCT07329894 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer
|
Phase 1 | Recruiting | 2026-02 | China |
|
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
NCT06316427 · ClinicalTrials.gov ↗ · T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | 2024-03 | China |
|
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07093411 · ClinicalTrials.gov ↗ · B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
|
Phase EARLY_PHASE1 | Recruiting | 2025-08 | China |
|
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
NCT06316856 · ClinicalTrials.gov ↗ · T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | 2024-06 | China |
|
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
NCT07242417 · ClinicalTrials.gov ↗ · Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
Drugs: Cyclophosphamide, Fludarabine |
Phase EARLY_PHASE1 | Recruiting | 2025-12 | China |
|
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
|
Phase 1/2 | Recruiting | 2024-10 | China |
|
Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy for r/r B-ALL: a Clinical Trial
NCT06326008 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
|
Phase 1 | Recruiting | 2026-03 | China |
|
A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma
NCT07520357 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma
Drug: SHR-A1904 |
Phase 2 | Not yet open | 2026-04 | China |
|
Safety and Efficacy of CT0494BCP in Participants With Advanced Gastric/Esophagogastric Junction Adenocarcinoma
NCT07538856 · ClinicalTrials.gov ↗ · Gastric, Gastric / Gastroesophageal Junction Adenocarcinoma
|
Observational | Not yet open | 2026-04 | China |
|
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
NCT07593911 · ClinicalTrials.gov ↗ · Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Multiple Sclerosis
|
Not applicable | Not yet open | 2026-06 | China |
|
A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma
NCT07014540 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinomas (NEC)
|
Phase 4 | Not yet open | 2025-06 | China |
|
A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia
NCT06729320 · ClinicalTrials.gov ↗ · Refractory Immune Effector Cell-related Hemocytopenia
|
Not applicable | Not yet open | 2024-12 | China |
|
A Phase II Study of PD-1/IL-2α-bias Bispecific Antibody Fusion Protein Monotherapy in Advanced Esophageal Squamous Cell Carcinoma After Failure of Prior ICI Plus Platinum-Based Chemotherapy
NCT07688291 · ClinicalTrials.gov ↗ · Esophageal Squamous Carcinoma Cell
|
Phase 2 | Not yet open | 2026-06 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 32 | 26 |
A trial with sites in more than one country appears in each of those registers.
Beijing GoBroad Hospital is the lead sponsor of 32 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 26 of its 32 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 6 drugs and biologicals as interventions. The most frequent are CT041 autologous CAR T-cell (1), Cyclophosphamide (1), Fludarabine (1), SHR-A1904 (1) and Tumor vaccine-induced specific T-cell (1). The number in brackets is how many of its trials name each drug.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.